Allogene Therapeutics Valuation
| ALLO Stock | USD 2.16 0.36 20.00% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Allogene Therapeutics shows a prevailing Real Value of $3.4 per share. The current price of the firm is $2.16. Our model approximates the value of Allogene Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 16.60 %, current valuation of 229.45 M, and Return On Equity of -0.54 as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.2828 | Enterprise Value | Enterprise Value Ebitda (1.04) | Price Sales 11.6 K | Enterprise Value Revenue 3.9 K |
Undervalued
Today
Please note that Allogene Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Allogene Therapeutics is based on 3 months time horizon. Increasing Allogene Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Allogene Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Allogene Stock. However, Allogene Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.16 | Real 3.4 | Target 7.38 | Hype 2.08 |
The intrinsic value of Allogene Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Allogene Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Allogene Therapeutics helps investors to forecast how Allogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Allogene Therapeutics more accurately as focusing exclusively on Allogene Therapeutics' fundamentals will not take into account other important factors: Allogene Therapeutics Cash |
|
Allogene Therapeutics Total Value Analysis
Allogene Therapeutics is presently expected to have valuation of 229.45 M with market capitalization of 404.51 M, debt of 90.76 M, and cash on hands of 490.49 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Allogene Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
229.45 M | 404.51 M | 90.76 M | 490.49 M |
Allogene Therapeutics Investor Information
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 0.98. The entity had not issued any dividends in recent years. Based on the key indicators related to Allogene Therapeutics' liquidity, profitability, solvency, and operating efficiency, Allogene Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Allogene Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Allogene Therapeutics has an asset utilization ratio of 0.004009 percent. This suggests that the Company is making $4.0E-5 for each dollar of assets. An increasing asset utilization means that Allogene Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Allogene Therapeutics Profitability Analysis
Based on Allogene Therapeutics' profitability indicators, Allogene Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Allogene Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-12-31 | Previous Quarter -50.9 M | Current Value -41.4 M | Quarterly Volatility 26.7 M |
For Allogene Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Allogene Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Allogene Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Allogene Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Allogene Therapeutics over time as well as its relative position and ranking within its peers.
Allogene Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Allogene Therapeutics is estimated to be -0.221425 with future projections ranging from a low of -0.3675 to a high of -0.10665. Allogene Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.98. Please be aware that the consensus of earnings estimates for Allogene Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Allogene Therapeutics Earnings Estimation Breakdown
The calculation of Allogene Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Allogene Therapeutics is estimated to be -0.221425 with the future projection ranging from a low of -0.3675 to a high of -0.10665. Please be aware that this consensus of annual earnings estimates for Allogene Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.37 Lowest | Expected EPS | -0.11 Highest |
Allogene Therapeutics Earnings Projection Consensus
Suppose the current estimates of Allogene Therapeutics' value are higher than the current market price of the Allogene Therapeutics stock. In this case, investors may conclude that Allogene Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Allogene Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 15 | 77.15% | 0.0 | -0.221425 | -0.98 |
Allogene Therapeutics Ownership Allocation
Allogene Therapeutics holds a total of 224.73 Million outstanding shares. Over half of Allogene Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Allogene Therapeutics Profitability Analysis
The company reported the previous year's revenue of 22 K. Net Loss for the year was (257.59 M) with loss before overhead, payroll, taxes, and interest of (166.49 M).About Allogene Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Allogene Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Allogene Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Allogene Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Allogene Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allogene Therapeutics. We calculate exposure to Allogene Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Allogene Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 25.3 K | 24 K | |
| Pretax Profit Margin | -13.4 K | -12.8 K | |
| Operating Profit Margin | -14.3 K | -13.6 K | |
| Net Loss | -13.5 K | -12.8 K | |
| Gross Profit Margin | (81.57) | (85.65) |
Allogene Therapeutics Current Valuation Indicators
Allogene Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Allogene Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Allogene Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Allogene Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Allogene Therapeutics' worth.When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.